Dorte Vendelbo Jensen

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

Merete Lund Hetland, Ib Jarle Christensen, Ulrik Tarp et al. · Arthritis & Rheumatism · 2009 · 529 citations

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Bente Glintborg, Inge Juul Sørensen, Anne Gitte Loft et al. · Annals of the Rheumatic Diseases · 2017 · 245 citations

Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor α Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry

Bente Glintborg, Mikkel Østergaard, Niels Steen Krogh et al. · Arthritis & Rheumatism · 2013 · 200 citations

Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO Registry

Lene Dreyer, Lene Mellemkjær, Anne Rødgaard Andersen et al. · Annals of the Rheumatic Diseases · 2012 · 175 citations · Full text

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

Bente Glintborg, Anne Gitte Loft, Emina Omerovic et al. · Annals of the Rheumatic Diseases · 2018 · 153 citations · Full text